Zinacef
Brand names,
Zinacef
Analogs
Zinacef
Brand Names Mixture
Zinacef
Chemical_Formula
C16H16N4O8S
Zinacef
RX_link
http://www.rxlist.com/cgi/generic/cefurox.htm
Zinacef
fda sheet
Zinacef
msds (material safety sheet)
Zinacef
Synthesis Reference
M. C. Cook et al., U.S. Pat. 4,267,320 (1977)
Zinacef
Molecular Weight
424.386 g/mol
Zinacef
Melting Point
218-225 oC
Zinacef
H2O Solubility
Freely soluble as sodium salt (145 mg/L)
Zinacef
State
Solid
Zinacef
LogP
-0.921
Zinacef
Dosage Forms
Powder; Powder for oral suspension; Tablet (125, 250, or 500 mg)
Zinacef
Indication
For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.
Zinacef
Pharmacology
Cefuroxime is a β-lactam type antibiotic. More specifically, it is a second-generation cephalosporin. Cephalosporins work the same way as penicillins: they interfere with the peptidoglycan synthesis of the bacterial wall by inhibiting the final transpeptidation needed for the cross-links. This effect is bactericidal. Cefuroxime is effective against the following organisms: Aerobic Gram-positive Microorganisms: Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes. Aerobic Gram-negative Microorganisms: Escherichia coli, Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis (including beta-lactamase-producing strains), Neisseria gonorrhoeae (including beta-lactamase-producing strains). Spirochetes: Borrelia burgdorferi.
Zinacef
Absorption
Absorbed from the gastrointestinal tract. Absorption is greater when taken after food (absolute bioavailability increases from 37% to 52%).
Zinacef
side effects and Toxicity
Allergic reactions might be expected, including rash, nasal congestion, cough, dry throat, eye irritation, or anaphylactic shock. Overdosage of cephalosporins can cause cerebral irritation leading to convulsions.
Zinacef
Patient Information
Patients should be counseled that antibacterial drugs including Cefuroxime for Injection USP and Dextrose
Injection USP should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common
cold). When Cefuroxime for Injection USP and Dextrose Injection USP is prescribed to treat a bacterial infection,
patients should be told that although it is common to feel better early in the course of therapy, the medication
should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the
effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and
will not be treatable by Cefuroxime for Injection USP and Dextrose Injection USP or other antibacterial drugs in the
future.
Zinacef
Organisms Affected
Enteric bacteria and other eubacteria